Munich, Germany and San Francisco, USA, September 15, 2025 – CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief Financial Officer and Chief Business Officer; Sujata Rao, MD, as Chief Medical Officer; Heike Krupka, PhD, as Chief Development Officer and Andrea Goddard as Chief Technology Officer represent a significant addition to the company's international development expertise.

Amsterdam, the Netherlands, September 09, 2025 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced the appointment of Roland W. Bürli, PhD, as Chief Scientific Officer (CSO), effective September 1, 2025. Dr. Bürli brings more than 25 years of experience in drug development and has held senior leadership roles across pharma and biotech companies.

Amsterdam, the Netherlands, September 03, 2025 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a publication in Nature on the role of ABHD18 as a missing link in the cardiolipin biosynthesis pathway. Cardiolipin is the signature phospholipid essential for mitochondrial function and implicated in both rare and common diseases. In a collaboration between Scenic and Dr. Jason Moffat's team at The Hospital for Sick Children (SickKids) in Toronto, the study aimed to identify modifier genes for Barth Syndrome (BTHS), an inborn error of cardiolipin metabolism, characterized by early onset cardiac and skeletal myopathy.

Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.

Schlieren / Zurich, Switzerland, 19 August, 2025 – Memo Therapeutics AG ("MTx") has published Phase I clinical data in Clinical and Translational Science, highlighting the safety, tolerability, and pharmacokinetics (PK) of its lead clinical asset, potravitug, a highly potent human monoclonal antibody targeting BK polyomavirus ("BKPyV").

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus ("BKPyV")-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients ("KTR").

Schlieren / Zurich, Switzerland, 19 June, 2025 – Memo Therapeutics AG (or "MTx") today announced that its late breaking abstract has been accepted for an oral presentation at the World Transplant Congress ("WTC") in San Francisco taking place 2-6 August 2025. The late breaking oral presentation will include interim results from the Phase II clinical trial evaluating potravitug.

Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or "MTx") has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development.

DIEPENBEEK, Belgium, (May 19, 2025) – Rejuvenate Biomed, an AI-enabled, clinical-stage biotech company developing safe, synergistic combination therapeutics that alter the course of age-related diseases, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating Rejuvenate Biomed's lead investigational compound, RJx-01, in patients with chronic obstructive pulmonary disease (COPD)-related muscle weakness and sarcopenia.

Amsterdam, the Netherlands, May 07, 2025 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a publication in Nature covering data on the discovery of PLA2G15 as a target for its lead program in neuro- and metabolic diseases. The publication, titled "PLA2G15 is a BMP Hydrolase and its Targeting Ameliorates Lysosomal Disease", is the result of an ongoing collaboration with the team of Dr. Monther Abu-Remaileh at Stanford University.